Abstract: A multi-stage process for the production of a Product Heavy Marine Fuel Oil compliant with ISO 8217: 2017 as a Table 2 residual marine fuel from a high sulfur Feedstock Heavy Marine Fuel Oil compliant with ISO 8217: 2017 as a Table 2 residual marine fuel except for the sulfur level, involving hydrotreating under reactive distillation conditions in a Reaction System composed of one or more reaction vessels. The reactive distillation conditions allow more than 75% by mass of the Process Mixture to exit the bottom of the reaction vessel as Product Heavy Marine Fuel Oil. The Product Heavy Marine Fuel Oil has a maximum sulfur content (ISO 14596 or ISO 8754) less than 0.5 mass %. A process plant for conducting the process for conducting the process is disclosed.

Abstract: Systems and methods of processing coal to form mesophase pitch include performing a low-severity direct coal liquefaction (LSDCL) process on a coal feedstock to produce a coal tar pitch therefrom. The systems and methods can include contacting coal directly with a catalyst in the presence of a solvent, pressurizing the coal in direct contact with the catalyst in the presence of the solvent to a predetermined pressure of about 1000 psia or less, heating the coal in direct contact with the catalyst in the presence of the solvent to a predetermined temperature of about 380° C. or less, and liquefying the coal to form a coal tar pitch. The coal tar pitch can be thermally treated to a liquid crystal phase exhibiting anisotropic spheres of mesophase and spun to form carbon fibers.

Abstract: The present invention describes a tall diesel composition obtainable from a crude tall oil, said tall diesel composition comprising carboxylic acids in a range of 50-98 wt % and neutral components in a range of 2-50 wt %, wherein the tall diesel composition comprises 1-20 wt % rosin acids, 6-35 wt % saturated fatty acids and 59-74 wt % unsaturated fatty acids.

Abstract: The present invention relates to an additive for fuels such as diesel fuel and fuel oil, used respectively for diesel engines and boilers of various types, comprising a metal oxidation catalyst, an organic nitrate and a dispersing agent in suitable ratios, capable of improving combustion efficiency in such a way as to reduce the formation of particulate matter and consumption.

Abstract: A microbial growth control agent and method of controlling microbial growth in metal working fluids, wherein the agent comprises at least a glycol ether amine.

Abstract: The present invention concerns the use of at least one polyorganosiloxane to release air from a lubricant composition comprising at least one base oil, when lubricating at least one moving part of an electric or hybrid vehicle.

Abstract: The present disclosure relates methods and systems for refining grain oil compositions using water, and related compositions produced therefrom. The present disclosure also relates to methods of using grain oil derived from a fermentation product in an anti-foam composition and/or feedstock to make diesel.

Abstract: An article includes a unit dose packet of a concentrated cleaning composition for cleaning laundry. The concentrated cleaning composition comprising a nonionic surfactant, fatty acid methyl ester sulfonate, fatty acid soap, one or a plurality of enzymes, and a solvent system. The cleaning composition is compatible with polyvinyl alcohol film. The unit dose packet includes the concentrated laundry cleaning composition disposed in a single chamber, dual chamber, or multi-chamber unit dose packet having a total weight of the concentrated cleaning composition of from 15 grams to 30 grams.

Abstract: The present disclosure pertains to surfactants for use in the formulation of detergents, foaming agents, emulsifiers, and degreasers. Some aspects of the invention include formulations suitable for cleaning and/or condition fabrics including upholstery. Some formulations are suitable for in home or commercial dry cleaning. Some of the formulations may be suitable for cleaning hard surfaces including plastic surfaces.

Abstract: The present invention relates to a surfactant booster for use in high foaming cleaning compositions. In an aspect of the invention, a C6, C7, C8, C9, C10, C11 or C12 linear alcohol in very low amounts is added to increase surface activity, foam and wetting properties of the composition. The alcohol is added in an amount of alcohol to surfactant of about 1:100 to 1:200 and must be linear. In another aspect, the invention relates to novel cleaning compositions such as pot and pan soaking compositions, dishwashing compositions, food and beverage foaming cleaners, vehicle cleaning and the like suitable for use in hard water, which can be solid or liquid. The invention further relates to methods of making these compositions, and to methods employing these compositions.

Abstract: An electrochemical biosensor based on magnetically coupled LC sensors for the rapid detection of microbial growth and sensitivity to microbials. The engineered LC sensors can be placed in 96 well plates and communicate the reading remotely with a receiver coil for signal analysis. The sensors were validated by testing the growth of Escherichia. coli, Staphylococcus. aureus, and Pseudomonas aeruginosa in the presence and absence of different antibiotics. Drug-resistant strains were used as controls. Bacterial growth was detected within 30 mins of culture inoculation, allowing rapid determination of antibiotic susceptibility at the phenotypic level. The pattern shown in the LC sensor AST is consistent with results collected with traditional optical density (OD) 600 nm measurement, additional validation was also performed with lysogeny broth (LB) dosed with fetal bovine serum (FBS). With the compatibility with 96-well plates, this rapid AST may be used for low-cost, point-of-care applications.

Abstract: Disclosed is a device for exposing an algal solution to light, for a photobioreactor, this exposure device including a flat support including at least one opening capable of holding at least one shaft, the shaft being made of a liquid-tight, translucent or even transparent flexible material, and including an open end capable of holding a sleeve, the sleeve being translucent, or even transparent, and arranged to seal and attach the shaft to the support. The exposure device has positive floatability in water. Also disclosed is a photobioreactor equipped with such a device and a start-up method for such a photobioreactor.

Abstract: An culture vessel includes one or more recesses, each having a flat bottom surface, and a side surface extending upward from the peripheral edge of the bottom surface and including a rough surface with arithmetic mean roughness of 0.18 ?m to 5.0 ?m. The rough surface is water repellent and reduces meniscus formation on the peripheral edge of the upper surface of the culture solution. This suppresses a reduction in light amount at the peripheral edges of recesses due to meniscus formation. On the side surfaces of recesses, secondary illumination light is diffused and reflected. This suppresses formation of an image (ghost) of a biological sample by the secondary illumination light. Accordingly, it is possible to suppress a reduction in the amount of light due to meniscus formation in the culture solution and to reduce formation of an image of the biological sample by the secondary illumination light.

Abstract: Cell culture systems and methods provide improved immunotherapeutic product manufacturing with greater scalability, flexibility, and automation. Cell culture systems are configured with interchangeable cartridges, allowing versatility and scalability. Systems are configured to have multiple connected cell culture chambers, which allows parallel processing of different types of cells. Gas-impermeable cell culture chambers and methods for generating cells in closed systems prevent contamination and user error. Methods for recycling cell culture medium provide additional efficiencies.

Abstract: An automated cell culture system with one or more pumps configured to operate on a duty cycle prevents excess heat generation, allowing the cell culture system to operate inside a conventional incubator without overheating. The duty cycle involves switching the pump between on and off modes. By running pumps for a short period of time and then shutting them off, less heat is produced. To account for the reduced pumping time during the cycle, the pump can be run at a higher flow rate while it is on, so that the average flow rate over the course of the cycle is not reduced. Systems of the invention employ duty cycles in which the on-cycle is shorter than the off-cycle, and particularly where the on-cycle is less than 20% of the duration of the entire duty cycle.

Abstract: The present disclosure is directed to the organic growth and phasing design for a system for the industrial growth of biologics. A system may include a number of subsystems, such as a buffer distribution subsystem, a media preparation subsystem, a bioreactor subsystem, a harvest subsystem, and/or a purification subsystem. The subsystems may be highly interconnected for flexible process flow design. Additionally, the subsystems may be constructed with a total output capacity with a total number of equipment stations and operated at a lower output capacity with fewer than the total equipment stations to maintain headroom for growth in phases.

Abstract: An interface for coupling a dissolved oxygen sensor to a single-use bioreactor container is provided. A dissolved oxygen (DO) window membrane is operably coupled to the single-use container and configured to position a DO sensor at least partially within the single-use container. In some embodiments, a DO window body mounts the DO window membrane at a distal end thereof. The DO window body can include a slide lock for facilitating positioning of a DO sensor within the DO window body. Additionally, the DO window body may include at least one heat exchange fin.

Abstract: An apparatus and method are provided for performing detection of microorganisms (e.g., viruses) with high sensitivity. The apparatus and method are well suited for point-of-care (POC) testing in resource-limited regions and are capable of being operated with very little manual intervention and without the need for lab equipment. A variety of viruses can be detected with high sensitivity, including, for example, coronaviruses, Zika virus and flu viruses.

Abstract: Disclosed are a rare cell capture system and an application thereof. The system comprises a fluid tube device, a circulation power apparatus device, a component capture device and an optional anticoagulant release device, the circulation power apparatus device and the component capture device being connected in series to a fluid circulation system via the fluid tube device to form an extracorporeal fluid circulation pathway, the component capture device comprising a microfluidic chip or a chipset. Also disclosed is a method for using the capture system to capture rare cells in blood. The system and the application thereof have the advantages of being large-capacity, in-line and low-hemolysis.

Abstract: The present disclosure relates to the technical field of microorganisms, in particular to Lactobacillus gasseri HMV18 and a secreted protein and an application thereof. The Lactobacillus gasseri HMV18 is preserved in the China Center for Type Culture Collection on Jul. 11, 2019 with a preservation number of CCTCC NO: M 2019538, and a preservation address of Wuhan University, Wuhan, China. The protein extracted from the Lactobacillus gasseri HMV18 has antibacterial and anti-tumor effects, but basically has no effect on normal myocardial cells, so the Lactobacillus gasseri HMV18 can be applied to preparation of antibacterial and anti-tumor products.

Abstract: A method for preparing a shelf stable spore-containing probiotic alimentary additive is disclosed, the method including providing a liquid slurry including spores from at least one spore-forming probiotic bacterial strain, a saccharide, and a humectant; and pasteurizing the liquid slurry to yield the alimentary additive. The alimentary additive may have a water activity (Aw) of less than about 0.7. The alimentary additive may have a pH from about 2.0 to 9.5. A plurality of the spores may remain in an un-germinated state and uniformly suspended for at least two months after the pasteurizing to yield a shelf stable spore-containing probiotic alimentary additive.

Abstract: A fermentation broth which includes a microbial cell which has been subjected to a condition under which the activity an endogenous transporter for 2? fucosyllactose is increased. Also provided are methods for increasing export of 2? fucosyllactose from a microbial cell, methods for identifying an endogenous yeast transporter of 2? fucosyllactose, and microbial cells genetically engineered to increase the activity of an endogenous transporter of 2? fucosyllactose.

Abstract: Disclosed herein are lysis reagents for lysing red blood cells, thereby releasing an analyte, such as RNA from a host or pathogen, in a form suitable for analysis. The reagent includes at least a buffer, a detergent and one or both of a chloride containing salt and an anti-coagulant. The reagent serves to lyse blood cells, protect the released analyte from degradation in the lysate, and is compatible with subsequent steps for analysis of the analyte such as target capture, amplification, detection, or sequencing.

Abstract: A method of target enrichment or depletion from a sample with an analyte is described. A probe has one of a left-handed PNA pair and a targeting moiety, in which the left-handed PNA pair are a complementary pair of PNAs that are chiral and have a cyclic backbone modification that induces a left-handed helical structure. A capture surface has the other of the left-handed PNA pair; and the left-handed PNA pair bind to hybridize the probe to the capture surface, which may be a magnetic bead.

Abstract: Disclosed herein include systems, methods, compositions, and kits for the labeling of nucleic acids targets. In some embodiments, the methods comprise the use of target-specific primers and target-non-specific primers during library preparation (e.g., hybrid library preparation). In some embodiments, the methods increase the abundance of select low abundance targets during cDNA library preparation and/or sequencing library preparation.

Abstract: Compositions, systems, and methods for the display of analytes such as biomolecules are described. Display of analytes is achieved by coupling of the analytes to displaying molecules that are configured to associate with surfaces or interfaces. Arrays of analytes may be formed from the described systems for utilization in assays and other methods.

Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.

Abstract: The disclosure provides polynucleotides encoding a polypeptide including a morpholino linker. In some embodiments, the polynucleotides of the invention have increased stability compared to wild-type polynucleotides.

Abstract: Disclosed herein are antibody oligonucleotide conjugates and pharmaceutical compositions that induce an alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping. Also described herein include methods for treating muscle dystrophy including Duchenne muscular dystrophy that comprises administering antibody oligonucleotide conjugates or a pharmaceutical composition that induces alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping.

Abstract: The present disclosure provides compositions comprising miR-3132 and one or more pharmaceutical agents that upregulate TNF-related apoptosis-inducing ligand (TRAIL) or activate TRAIL signaling pathway, and methods for treating a cancer comprising administering miR-3132, or a composition comprising miR-3132 and one or more pharmaceutical agents that upregulate TRAIL or activate TRAIL signaling pathway, to a subject.

Abstract: Disclosed herein polynucleotides complementary to IL-34, including IL-34 antisense oligonucleotides and IL-34 NAs, and methods for treating inflammatory diseases, such as an inflammatory bowel disease, and/or fibrosis, associated with elevated activity or expression of IL-34. Also disclosed are pharmaceutical compositions containing a polynucleotide complementary to IL-34, for example, an IL-34 antisense oligonucleotide or an IL-34 siRNA, useful for treating inflammatory diseases and/or fibrosis and manufacture of medicaments containing a disclosed polynucleotide to be used in treating inflammatory diseases and/or fibrosis.

Abstract: The purpose of the present invention is to provide an antisense oligonucleotide that targets an ARL4C molecule and exerts an antitumor effect in vivo, and a nucleic acid drug using the antisense oligonucleotide. An antisense oligonucleotide that has a base sequence consisting of at least 10 consecutive bases contained in the base sequence represented by SEQ ID NO: 1. This antisense oligonucleotide targets an ARL4C molecule and thus can inhibit the expression of ARL4C in a tumor cell in vitro and suppress the migration and proliferation thereof. When systemically administered, moreover, the antisense oligonucleotide can exert an excellent antitumor effect in vivo too.

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modulatory polynucleotides.

Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.

Abstract: Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Abstract: The present invention provides novel DNA molecules and constructs, including their nucleotide sequences, useful for modulating gene expression in plants and plant cells. The invention also provides transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides, along with methods of their use.

Abstract: The present invention provides wheat grain comprising (1,3;1,4)-?-D-glucan (BG). The wheat grain is characterised by one or more of the following features; a BG content of at least 3% (w/w); the BG of the grain has a DP3/DP4 ratio between about 1.0 and about 2.0 or between about 1.0 and 2.3; and the BG is partially water soluble such that between 8.0% and about 25% or between about 10% and about 25% of the BG of the grain is water soluble. The present invention also provides uses of this grain.

Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity.

Abstract: The present invention relates to an adenoviral vector comprising a regulatable Major Late Promoter and an exogenous transgene. The invention also provides cells comprising such adenoviral vectors, and processes using such vectors.

Abstract: Disclosed are live, chimeric non-human Mononegavirales vectors that allow a cell to express at least one protein from at least one human pathogen. In addition, compositions comprising the vectors, methods and kits for eliciting an immune response in a host, and methods of making the vectors are disclosed, in accordance with embodiments of the invention.

Abstract: The present disclosure provides the gene therapy compositions comprising vectors (e.g., viral vectors) suitable for delivery of nucleic acids encoding immunomodulatory proteins or functional fragments thereof, and methods of using the same. Certain aspects of the disclosure are directed to an adeno-viral vector (AAV) delivery of nucleic acids encoding two or more immunomodulatory proteins or functional fragments thereof to a tumor.

Abstract: Described herein are cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derided cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines. Also disclosed are methods of using the described cells and media, such as therapeutic methods of use for the described cells. The described cells include iPSC-derived mesodermal precursor cells (MPC), which itself may differentiate into at least four different cell types. When cultured under appropriate conditions, the mesodermal precursor cells can be used to produce hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), smooth muscle cells (SMC), or unlimited functional endothelial cells (UFEC). One characteristic that makes the described cells desirable is that they can be maintained in culture for a number of days, or passages, without changing phenotype through differentiation.

Abstract: The invention relates to the field of cell therapy and to an in vitro method for generating T-cell progenitors, comprising the step of exposing CD34+ cells in a medium containing a Notch ligand, a soluble domain of the Delta-like ligand 4, joined to an Fc region of a protein IgG, in the presence of a fragment of fibronectin comprising the motifs RGDS and CS-1 and a heparin-binding domain.

Abstract: The present invention provides novel attenuated Pasteurella multocida strains that may be used, in live or killed form, to formulate vaccines that are highly protective against P. multocida infection in bovines, other mammals, and in birds. The present invention also identifies the combination of nanP and hyaC gene mutations as key to the provision of such vaccines. When appropriately formulated, antigenic material of numerous other bovine pathogens may be combined with the live attenuated Pasteurella multocida strains, to make effective combination vaccines.

Abstract: The present invention relates to a composition or combination for the production of butanol and isopropanol, comprising an acetone-butanol-ethanol (ABE)-producing Clostridium strain and a genetically engineered B. subtilis strain, wherein said genetically engineered B. subtilis strain has been transformed by at least one polynucleotide molecule; the at least one polynucleotide molecule comprising a secondary alcohol dehydrogenase gene operably linked to at least one promoter. The invention also relates to methods of producing butanol and isopropanol in a co-culture, methods of producing butyrate, isopropanol and butanol in a co-culture and methods of producing esters.

Abstract: The present invention relates to variants of Terminal deoxynucleotidyl Transferase (TdT), each of which (i) has an amino acid sequence similarity to SEQ ID NO: 2. 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35 with corresponding amino acid substitutions, (ii) is capable of synthesizing a nucleic acid fragment without a template and (iii) is capable of incorporating a modified nucleotide into the nucleic acid fragment.

Abstract: A polynucleotide encoding a ThermoCas9 protein from Geobacillus thermodenitrificans and a constitutive promoter are used to engineer eukaryotic cells, e.g. fungi, yeast or algae, so that the ThermoCas9 endonuclease is integrated and expressed from the genome of the cell. Then, a second expression plasmid is used to transfect these ThermoCas9 expressing cells, the second plasmid containing an inducible promoter and a polynucleotide encoding a guide RNA. The guide RNA combines with the ThermoCas9 to provide the targeted endonuclease activity to cleave the cell DNA at a desired locus or gene of interest. A repair-oligo is also provided to the cell whereby following DNA cleavage, homologous recombination takes place in the cell with the repair-oligo so that either a deletion or substitution of nucleotides in the locus or gene of interest is achieved. Expression vectors and methods of using the vectors to achieve ThermoCas9 mediated gene editing are described whereby higher temperatures, e.g. greater than 30° C.

Abstract: Materials and methods for gene editing using improved targeted endonucleases and endonuclease systems (e.g., Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) endonuclease systems) are provided herein.

Abstract: Compositions and methods related to Cas proteins, nucleic acids encoding the Cas proteins, and modified host cells comprising the Cas proteins and/or encoding nucleic acids are disclosed. Cas proteins are useful in a variety of applications. Cas proteins bind guide RNAs that in turn provide functional specificity to the Cas proteins, nucleic acids encoding the Cas guide RNAs, and modified host cells comprising the Cas guide RNAs and/or encoding nucleic acids. The Cas polypeptides and corresponding guide RNAs can be used in a variety of applications.

Abstract: The present invention provides engineered amylase polypeptides and compositions thereof. The engineered amylase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) conditions. The invention also relates to the use of the compositions comprising the engineered amylase polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered amylase polypeptides, as well as methods for making the engineered polynucleotides and amylase polypeptides.